Market Cap | 20.19M | P/E | - | EPS this Y | 69.90% | Ern Qtrly Grth | - |
Income | -38.76M | Forward P/E | 6.87 | EPS next Y | 148.00% | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -82.00% |
Recommedations | 2.50 | Quick Ratio | 0.04 | Shares Outstanding | 24.46M | 52W Low Chg | 27.00% |
Insider Own | 13.78% | ROA | -65.27% | Shares Float | 18.37M | Beta | 0.44 |
Inst Own | 29.91% | ROE | - | Shares Shorted/Prior | 493.55K/898.08K | Price | 0.82 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 169,687 | Target Price | 1.50 |
Oper. Margin | - | Earnings Date | Mar 25 | Volume | 188,362 | Change | -2.83% |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts. As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc.
HC Wainwright & Co. | Neutral | Sep 5, 23 |
Roth Capital | Neutral | Sep 1, 23 |
Roth MKM | Neutral | Sep 1, 23 |
HC Wainwright & Co. | Buy | Mar 28, 23 |
EF Hutton | Buy | Mar 20, 23 |
EF Hutton | Buy | Feb 2, 22 |
Needham | Hold | Jun 25, 19 |
Wedbush | Outperform | May 23, 19 |
Needham | Buy | Dec 20, 18 |